Marina Etchebehere
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marina Etchebehere has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Caroline Torricelli
Division of Nuclear Medicine, University of Campinas (UNICAMP), Campinas 13083-888, Brazil
1 shared publication - Elba Etchebehere
Division of Nuclear Medicine, University of Campinas (UNICAMP), Campinas, Brazil
1 shared publication - Ellen Nogueira-Lima
Division of Nuclear Medicine, University of Campinas (UNICAMP), Campinas 13083-888, Brazil
1 shared publication - Helena Lima
Faculdade de Medicina, Pontifícia Universidade Católica de Campinas (PUCC), Campinas 13087-571, Brazil
1 shared publication - Mariana Lima
Division of Nuclear Medicine, University of Campinas (UNICAMP), Campinas 13083-888, Brazil
1 shared publication - Mateos Bogoni
Hospital Erasto Gaertner, Curitiba 81520-060, Brazil
1 shared publication
Latest Publications
- Open Access
- 5 November 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (11) , 1483
Theranostics Nuclear Medicine in Prostate Cancer
Theranostic Nuclear Medicine is based on the idea of combining the same molecule (or drug) with different radioisotopes for both diagnosis and treatment, a concept that emerged in the early 1940s with the use of radioactive iodine for thyroid diseases. Theranostic Nuclear Medicine has since expanded to diseases of higher incidence, such as prostate cancer, with several imaging methods used to assess the extent of the disease and the corresponding radiopharmaceuticals used for treatment. For example, by detecting osteoblastic metastases by bone scintigraphy, corresponding radiopharmaceuticals with therapeutic properties can be administered to eliminate or reduce pain associated with metastases and/or determine overall survival gain. The purpose of this review is to discuss the role of Theranostic Nuclear Medicine in prostate cancer, addressing the main diagnostic imaging studies with their corresponding treatments in the Theranostic model.
- 5 November 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (11) , 1483
Open AccessTheranostics Nuclear Medicine in Prostate Cancer
Theranostic Nuclear Medicine is based on the idea of combining the same molecule (or drug) with different radioisotopes for both diagnosis and treatment, a concept that emerged in the early 1940s with the use of radioactive iodine for thyroid diseases. Theranostic Nuclear Medicine has since expanded to diseases of higher incidence, such as prostate cancer, with several imaging methods used to assess the extent of the disease and the corresponding radiopharmaceuticals used for treatment. For example, by detecting osteoblastic metastases by bone scintigraphy, corresponding radiopharmaceuticals with therapeutic properties can be administered to eliminate or reduce pain associated with metastases and/or determine overall survival gain. The purpose of this review is to discuss the role of Theranostic Nuclear Medicine in prostate cancer, addressing the main diagnostic imaging studies with their corresponding treatments in the Theranostic model.